New findings on pre-exposure prophylaxis (PrEP) from both CDC and NIH were among the HIV research findings shared on July 21 at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver, Canada. Below are highlights of some of the information they have shared.

CDC Study Finds High Adherence to Daily PrEP among Both Men and Women

The Centers for Disease Control and Prevention released new research showing high adherence to daily oral PrEP for HIV prevention among heterosexual men and women in Botswana. The data come from a 12-month open-label extension of the study known as TDF2. Key findings include:

• Both men and women were highly adherent to daily PrEP throughout the study period
• There were no HIV infections among study participants
• There was no increase in sexual risk behavior – in fact, sexual risk behavior among participants declined over the course of the study

Because an open-label extension more closely replicates a real-world setting than the preceding clinical trial, the findings may provide a better indication of likely PrEP adherence and effectiveness outside of a research setting. Read the full CDC news release.

NIAID Study Finds PrEP Use Feasible among High-Risk Groups in U.S. Community Settings

A majority of men who have sex with men and transgender women at high risk for HIV infection took anti-HIV medication for PrEP most of the time in a multi-site U.S. study examining use of this HIV prevention strategy outside of a clinical trial. NIAID funded the study, called the PrEP Demo Project. Read the NIAID media release about the study.

Young South African Women Can Adhere to Daily PrEP Regimen as HIV Prevention, NIH Study Finds

A clinical study funded by the NIH has found that young, single, black women in South Africa adhered to a daily pill regimen to prevent HIV infection—an HIV prevention strategy known as pre-exposure prophylaxis, or PrEP. This finding is the first strong indication that this population at substantial HIV risk could accept and reliably adhere to daily PrEP dosing. Men who have sex with men and transgender women in New York and Thailand also successfully adhered to daily dosing in the HIV Prevention Trials Network (HPTN) 067 trial, also known as the Alternative Dosing to Augment Pre-Exposure Prophylaxis Pill Taking (ADAPT) study. Read the news release and other conference information at the conference web site www.ias2015.orgExit Disclaimer.